within Pharmacolibrary.Drugs.ATC.N;

model N06AG02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 20 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.025,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) used primarily as an antidepressant for the treatment of major depressive disorder and social phobia. It is approved in some countries for these indications, though not in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both sexes, aged 18-65 years, after single oral dose.</p><h4>References</h4><ol><li><p>Guentert, TW, et al., &amp; Schoerlin, MP (1990). Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. <i>Acta psychiatrica Scandinavica. Supplementum</i> 360 91–93. DOI:<a href=&quot;https://doi.org/10.1111/j.1600-0447.1990.tb05345.x&quot;>10.1111/j.1600-0447.1990.tb05345.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2248087/&quot;>https://pubmed.ncbi.nlm.nih.gov/2248087</a></p></li><li><p>Mayersohn, M, &amp; Guentert, TW (1995). Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. <i>Clinical pharmacokinetics</i> 29(5) 292–332. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199529050-00002&quot;>10.2165/00003088-199529050-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8582117/&quot;>https://pubmed.ncbi.nlm.nih.gov/8582117</a></p></li><li><p>Wiesel, FA, et al., &amp; Kettler, R (1985). Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. <i>European journal of clinical pharmacology</i> 28(1) 89–95. DOI:<a href=&quot;https://doi.org/10.1007/BF00635714&quot;>10.1007/BF00635714</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3987791/&quot;>https://pubmed.ncbi.nlm.nih.gov/3987791</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06AG02;
